跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
HADLIMA PUSHTOUCH - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
HADLIMA PUSHTOUCH
Authorized
STANDARD
HADLIMA PUSHTOUCH
Samsung Bioepis Co., Ltd.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
d739be18f099edb6
Company
Samsung Bioepis Co., Ltd.
Type
Standard
Approval Details
Approval Id
d739be18f099edb6
Drug Approval Canada Name
HADLIMA PUSHTOUCH
Product Name
HADLIMA PUSHTOUCH
Status
Marketed
Status Date
2023-10-25
Original Market Date
2023-10-25
Din
02533480
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
90:24.16.92
Atc Original
L04AB04 ADALIMUMAB
Atc Name
l 04 ab 04
Aig Number
0150364002
Company Name
Samsung Bioepis Co., Ltd.
Company Address
76, Songdogyoyuk-Ro, Yeonsu-Gu, Incheon, Incheon, Korea, Republic Of, 21987
Company Detail Path
/organization/samsung-bioepis-co-ltd
Company Information
Pharmaceutical Company Name
Samsung Bioepis Co., Ltd.
Country Name
South Korea
Province Name
Incheon
City Name
incheon,incheon,country_kr
Address
76 Songdogyoyuk-ro, Yeonsu-gu
Website
http://www.samsungbioepis.com
Active Ingredients
ADALIMUMAB
40 MG / 0.4 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
d739be18f099edb6
Type
Standard
Back to Health Canada Approvals